Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model

Kotańska, Magdalena and Mika, Kamil and Sałaciak, Kinga and Wheeler, Lee and Sapa, Jacek and Kieć-Kononowicz, Katarzyna and Pytka, Karolina (2020) Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model. Pharmacology Biochemistry and Behavior, 196. 172974. ISSN 1873-5177

[thumbnail of Kotanska-etal-PBB-2020-Pitolisant-protects-mice-chronically-treated-with-corticosterone]
Preview
Text (Kotanska-etal-PBB-2020-Pitolisant-protects-mice-chronically-treated-with-corticosterone)
Kotanska_etal_PBB_2020_Pitolisant_protects_mice_chronically_treated_with_corticosterone.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (854kB)| Preview

    Abstract

    Purpose: Histamine H3 receptor ligands may have antidepressant and anxiolytic effects. They can also compensate for metabolic disorders, which affect glucose or triglyceride levels. In previous studies, we have shown that pitolisant, a histamine H3 receptor antagonist/inverse agonist and σ1 receptor agonist, prevented the development of certain metabolic and depressive-like disorders in mice that have been treated chronically with olanzapine. Methods: As a continuation of our previous experiments, this study aimed to investigate the antidepressant- and anxiolytic-like activity of pitolisant in mice using the corticosterone-induced depression model. The forced swim and the elevated plus maze tests were used as behavioral endpoints. We also studied the effect pitolisant had on the level of acetoacetic acid in the urine as well as the glucose tolerance and body weight of the mice that had been administered corticosterone. Results: Pitolisant (10 mg/kg b.w.) did not prevent depressive-like behavior in mice during the chronic corticosterone administration but did counteract anxiety-like behavior, whilst fluoxetine (10 mg/kg) was shown to protect the mice from both of these behaviors. None of the treatments that were used in the study showed an effect on the locomotor activity of the mice. Pitolisant did not prevent an increase in acetoacetic acid levels in the urine, nor did it improve glucose tolerance in the tested mice. Conclusion: Although literature data indicates that there is significant potential for finding an antidepressant and anti-diabetic drug among the histamine H3 and σ1 receptor ligands, in our study, pitolisant was shown to only slightly compensate for corticosterone-induced abnormalities. However, further research will be required to study pitolisant's anxiolytic-like activity.

    ORCID iDs

    Kotańska, Magdalena, Mika, Kamil, Sałaciak, Kinga, Wheeler, Lee ORCID logoORCID: https://orcid.org/0000-0002-9132-1875, Sapa, Jacek, Kieć-Kononowicz, Katarzyna and Pytka, Karolina;